Prostate Cancer Clinical Trials in Baltimore

Showing 1-20 of 342 trials

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.

High-Risk Localized Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60 participantsStarted Apr 2026

Baltimore, Maryland, United States

RECRUITINGPhase 1/2< 1 mile

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

CancerColorectal CancerSolid Tumor+12 more

Parabilis Medicines, Inc.595 participantsStarted May 2023

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +22 more locations

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Prostate Cancer Trials in Other Cities

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Fusion Guided Focal Laser Ablation of Prostate Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Other Conditions in Baltimore